Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
The aggregate market value of the registrant’s common stock held
by non-affiliates of the registrant was $87,757,186 based on the closing sales price on the Nasdaq Stock Market as of December 31, 2020, the
last business day of the registrant’s most recently completed second fiscal quarter.
As of August 27, 2021, there were 10,011,301 shares of common stock,
par value $0.0001 per share, issued and outstanding.
This Annual Report on Form 10-K
contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, or the Securities Act, and Section 21E
of the Securities Exchange Act of 1934, or the Exchange Act. The statements contained in this report that are not purely historical are
forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management’s
expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts
or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The
words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,”
“project,” “should,” “would” and similar expressions may identify forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this report may include,
for example, statements about our:
The forward-looking
statements contained in this report are based on our current expectations and beliefs concerning future developments and their
potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated.
These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other
assumptions that may cause actual results or performance to be materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading
“Risk Factors.” Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove
incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no
obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as may be required under applicable securities laws and/or if and when management knows or has a reasonable basis on which to
conclude that previously disclosed projections are no longer reasonably attainable.
Introduction
We are a blank check company
incorporated in the State of Delaware on December 18, 2019 for the purpose of effecting a merger, share exchange, asset acquisition,
share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus
as our initial business combination.
On November 24, 2020, we consummated
the IPO of 8,009,041 shares of our common stock (“Public Shares”), which includes the partial exercise by the underwriter
of its over-allotment option in the amount of 509,041 Public Shares, at a price of $10.00 per Public Share, generating gross proceeds
of $80,090,412. Simultaneously with the closing of the IPO, we consummated the sale of 3,146,454 private warrants (“Private Warrants”)
to the Sponsor at a price of $0.90 per Private Warrant, generating gross proceeds of $2,831,809. The Private Warrants were issued pursuant
to Section 4(a)(2) of the Securities Act of 1933, as amended, as the transaction did not involve a public offering.
The Company granted the underwriters
a 45-day option from the date of the IPO to purchase up to 1,125,000 additional Public Shares to cover over-allotments, if any, at the
IPO price less the underwriting discounts and commissions. As a result of the underwriter’s election to partially exercise the over-allotment
option to purchase an additional 509,041 Public Shares, a total of 615,959 Public Shares remained available for purchase at a price of
$10.00 per Public Share. On January 8, 2021, the underwriters’ election to exercise their remaining over-allotment option expired
unexercised.
Following the closing of the
IPO on November 24, 2020, an amount of $80,090,412 ($10.00 per Public Share) from the net proceeds of the sale of the Public Shares in
the IPO and the sale of the Private Warrants was placed in a trust account (the “Trust Account”), and invested in U.S. government
securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended, or the Investment Company
Act, with a maturity of 183 days or less or in any open-ended investment company that holds itself out as a money market fund meeting
the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of
a Business Combination or (ii) the distribution of the funds in the Trust Account as described below. The proceeds in the trust account
will not be released until the earlier of: (1) the completion of an initial business combination by November 24, 2022 and (2) our redemption
of 100% of the outstanding public shares if we have not completed a business combination in the required time period.
On January 1, 2020, we
issued an aggregate of 2,156,250 shares of common stock (the “founder shares”) to the Sponsor for an aggregate purchase
price of $25,000. On September 30, 2020, LifeSci Holdings LLC transferred 215,625 founder shares to Chardan Healthcare Investments
LLC, an investor in the Sponsor. The founder shares included an aggregate of up to 153,990 shares of common stock that remained
subject to forfeiture by the Sponsor, following the underwriters’ election to partially exercise their over-allotment option
so that the number of founder shares would collectively represent 20% of our issued and outstanding shares upon the completion of
the IPO. On January 8, 2021, the underwriters’ election to exercise their remaining over-allotment option expired unexercised,
resulting in 615,959 shares no longer subject to forfeiture and the forfeiture of 153,990 shares. Accordingly, as of January 8,
2021, there are 2,002,260 founder shares issued and outstanding.
Merger Agreement
On May 6, 2021, we entered into an Agreement and
Plan of Merger (the “Merger Agreement”) with LifeSci Acquisition II Merger Sub, Inc. (“Merger Sub”), and Science
37, Inc. (“Science 37”), pursuant to which the Merger Sub will merge with and into Science 37, with Science 37 surviving the
merger as our wholly-owned subsidiary (the “Merger”). Our board of directors has unanimously (i) approved and declared advisable
the Merger Agreement, the Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Merger
Agreement and related matters by our stockholders.
Treatment of Science 37
Securities:
Preferred
Stock. Immediately prior to the effective time of the Merger (the “Effective Time”) and subject to the consent
of the holders of a majority of the then outstanding shares of Science 37’s Series A, Series, B, Series C, Series D and Series D-1
preferred stock, par value $0.0001 per share (collectively, the “Science 37 Preferred Stock”), voting together as a single
class on an as-converted basis, each issued and outstanding share of Science 37 Preferred Stock will be converted into shares of the common
stock, par value $0.0001 per share, of Science 37 (the “Science 37 Common Stock”) at the then-applicable conversion rates
(the “Science 37 Preferred Stock Conversion”).
Warrants.
At the Effective Time, each outstanding and unexercised warrant to purchase shares of Science 37 capital stock (“Science 37 Warrant”)
that is outstanding and unexercised immediately prior to the Effective Time will be converted into a warrant exercisable to receive our
common stock, in accordance with its terms. From and after the Effective Time: (i) each Science 37 Warrant assumed by us may be exercised
solely for shares of our common stock; (ii) the number of shares of our common stock subject to each Science 37 Warrant assumed by us
will be determined by multiplying (A) the number of shares of Science 37 Common Stock, or the number of shares of Science 37 Common Stock
issuable upon exercise of the Science 37 Warrant that were subject to such Science 37 Warrant immediately prior to the Effective Time,
by (B) the Exchange Ratio, and rounding the resulting number up to the nearest whole number of shares of our common stock; (iii) the per
share exercise price for our common stock issuable upon exercise of each Science 37 Warrant assumed by us will be determined by dividing
the per share exercise price of Science 37 Common Stock subject to the Science 37 Warrant, as in effect immediately prior to the Effective
Time, by the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent; and (iv) any restriction on any Science
37 Warrant assumed by us will continue in full force and effect and the terms and other provisions of such Science 37 Warrant will otherwise
remain unchanged. The Exchange Ratio is defined in the Merger Agreement to be the quotient of (i) 100,000,000 divided by (ii) the number
of shares of Science 37’s Fully Diluted Capital Stock (as defined in the Merger Agreement).
Common
Stock. At the Effective Time, following the Science 37 Preferred Stock Conversion, each share of Science 37 Common Stock (including
shares of Science 37 Common Stock outstanding as a result of the Science 37 Preferred Stock Conversion, but excluding shares the holders
of which perfect rights of appraisal under Delaware law) will be converted into the right to receive such number of shares of our common
stock equal to the Exchange Ratio (subject to rounding mechanisms as described in the Merger Agreement) and a number of Earn-Out Shares
(as defined below).
Stock
Options. At the Effective Time, each outstanding option to purchase shares of Science 37 Common Stock, whether or not then
vested and exercisable, will be converted automatically (and without any required action on the part of such holder of outstanding option)
into an option to purchase shares of our common stock equal to the number of shares subject to such option prior to the Effective Time
multiplied by the Exchange Ratio, with the per share exercise price equal to the exercise price prior to the Effective Time divided by
the Exchange Ratio.
Earn-Out
Shares. Following the closing of the Merger, former holders of shares of Science 37 Common Stock (including shares received
as a result of the Science 37 Preferred Stock Conversion) and former holders of Science 37 stock options will be entitled to receive their
pro rata share of up to 12,500,000 additional shares of our common stock (the “Earn-Out Shares”) if, within a three-year period
following May 6, 2021, the signing date of the Merger Agreement, the closing share price of our common stock equals or exceeds any of
two thresholds over any 20 trading days within a 30-day trading period (each, a “Triggering Event”) and, in respect of a former
holder of Science 37 stock options, the holder continues to provide services to us or one of our subsidiaries at the time of such Triggering
Event.
The Merger Agreement contains
customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain
conditions as further described in the Merger Agreement.
For more information about the
Merger Agreement, the Merger and related transactions, see “Proposal 1 — The Business Combination Proposal”
in our Registration Statement on Form
S-4 filed with the SEC on July 28, 2021, and the proxy statement/prospectus a part thereof.
General
We are a blank check company
formed under the laws of the State of Delaware on December 18, 2019. We were formed for the purpose of effecting a merger, share
exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer
to throughout this prospectus as our initial business combination. Although there is no restriction or limitation on what industry our
target operates in, it is our intention to pursue prospective targets that are focused on healthcare innovation. We anticipate targeting
companies domiciled in North America or Europe that are developing assets in the biopharma, medical technology, digital health, and healthcare
services sectors, which aligns with our management team’s experience in healthcare investing and drug development.
Our Sponsor and Competitive Advantages
Our Sponsor is an affiliate
of LifeSci Capital LLC, a research-driven investment bank with deep domain expertise in the life sciences, LifeSci Advisors LLC, an investor
relations and public relations company in the life sciences industry with comprehensive solutions to communications and investor outreach,
and LifeSci Venture Management LLC, a corporate venture capital firm that seeks to invest in biotech and health sectors, collectively
“LifeSci”.
LifeSci’s service model
as a boutique investment bank is unique in that it exclusively serves corporate clients that are emerging life science companies that
discover, develop, and commercialize innovative products.
LifeSci’s service model
as an investor relations and public relations firm is unique in that it provides companies in the life sciences industry with comprehensive
solutions to communications and investor outreach. LifeSci assists companies in increasing visibility within the investment community
and educating investors on opportunities offered by these companies. LifeSci’s core capabilities include non-deal roadshow planning
and execution, KOL Events/R&D Days, corporate communications, and public relations through its affiliate LifeSci Public Relations.
LifeSci’s service model
as a venture capital firm is unique in that it focuses on pre-public institutional rounds of transformational healthcare companies managed
by exceptional founder/entrepreneurs. LifeSci’s investment principals have broad-ranging life sciences experience including public
and private investing, deal structuring, investment banking, equity capital markets, equity research, and bench research - both basic
science and applied.
LifeSci’s team is
comprised of individuals with medical and advanced scientific training and legal and banking experience, enabling a deeply
differentiated approach to research and idea generation. Complementing LifeSci’s scientific insight and industry relationships
is LifeSci’s business team, whose members include portfolio managers, corporate managers, and investment bankers who actively
engage with banks and academic institutions, cultivating strong relationships and expanding their network of key contacts and
syndicate partners. We believe the well-rounded nature of the team, strengthened by strong ties across industry, academia, banking
platforms, and unaffiliated investor relationships, will enhance our management team’s ability to source viable prospective
target businesses, capitalize them, and ensure public-market readiness.
Our independent directors
have extensive experience in clinical medicine, development and regulatory, operational, and management leadership within the healthcare
and financial industries. We believe that their breadth of experience will bolster our ability to thoroughly evaluate prospective candidates
and successfully execute our initial business combination. We believe our independent directors fortify our ongoing operations by providing
sound and experienced counsel on potential further acquisitions, divestitures, corporate strategy, and human resources.
We believe that our management
team is equipped with the knowledge, experience, capital and human resources, and sustainable corporate governance practices to pursue
unique opportunities that will offer attractive risk-adjusted returns.
Our management team is led
by Andrew McDonald, Co-Founder of LifeSci Advisors and LifeSci Capital, Michael Rice, Co-Founder of LifeSci Advisors and LifeSci Capital
and David Dobkin, Managing Director of LifeSci Capital.
We believe that our company’s
philosophical alignment with LifeSci, and our ability to leverage the rigorous and comprehensive scientific and financial analysis that
LifeSci is known for, provides us with a strong competitive advantage. LifeSci focuses on dynamic sectors of healthcare with great potential
to transform the healthcare industry: biotechnology, specialty pharmaceuticals, medical devices, digital health, information technology,
and healthcare services.
In 2018, LifeSci’s investors
relations hosted over 1,500 meetings in 27 key regions in the United States and over 500 meetings in 16 key regions throughout Europe.
In 2019, LifeSci’s Public Relations group secured over 1,300 media hits for their clients, with more than 100 million viewers and
readers globally, and wrote over 4,000 social media posts. LifeSci Venture’s first fund in 2017 has invested in 12 companies alongside
large dedicated healthcare funds and has launched its second fund in the third quarter of 2019. LifeSci’s investment bank has executed
over 50 transactions since inception, in which over 50% were repeat or Lead Managed. LifeSci’s investment bank core capabilities
include experienced-based investment banking advisory, varied capital raising abilities, industry insight and accessibility, global institutional
coverage and reach, equity research, and client empowerment.
LifeSci’s investor relations
presence has continued to expand year-over-year. In 2019, LifeSci Advisors conducted 4,602 one-on-one non-deal roadshow (NDR) investor
meetings, 140 key opinion leader (KOL) events, 594 meetings with high net worth (HNW) individuals and financial advisors, and 4,160 one-on-one
meetings at the J.P. Morgan healthcare conference (JPM), as compared to 4,105 NDR meetings, 130 KOL events, 568 HNW meetings, and 2,700
one-on-one meetings at JPM in 2018. Additionally, LifeSci’s Executive Search group completed 30 board and executive placements in
2019, up from 17 in 2018. LifeSci’s client base continues to grow as well, reaching 177 healthcare client partnerships in 2019,
up from 150 in 2018. LifeSci Partners has a global footprint, with offices in cities including New York, Chicago, Boston, Charlotte, London,
Geneva, Paris, and Tel Aviv.
Industry Opportunity
The healthcare industry consists
of sectors within the economic system providing curative, preventive, rehabilitative, and palliative care for patients. The industry includes
organizations providing such goods and services, as well as the doctors, nurses, and other healthcare employees. Total healthcare spending
in the United States reached nearly $3.5 trillion in 2017 and is expected to grow by an average 5.6 percent annually over 2016-2025, according
to a Centers for Medicare & Medicaid Services report released in February 2017. Total healthcare expenditures are thus expected
rise to 19.9 percent of the US Gross Domestic Product.
The healthcare market globally
mirrors a similar trend in the US of an increased contribution to the economy, due to the aging of the global population and other durable
macro dynamics. For example, in good part due to the impact of healthcare on society, life expectancy in the U.S. increased from 47 years
in 1900 to 79 years in 2016. As a disproportionate amount of overall healthcare spending is associated with diseases of aging, the aging
of the global population will continue to drive increased healthcare consumption. In addition, less developed countries have gone through
an unprecedented period of healthcare insurance and infrastructure expansion that has led the countries to have significantly higher contributions
to the global healthcare marketplace.
The target universe of healthcare
opportunities is extensive, considering healthcare’s overall contribution to the economy. A factor that further broadens the universe
is the high amount of innovation occurring within healthcare. In the wake of the genomics revolution, the pace of innovation is accelerating.
With the streamlining of the externalization of breakthrough science from academic institutions, particularly in the United States, as
mandates shifted from protecting intellectual property to externalizing it, increasing numbers of potentially disruptive healthcare innovations
exist that may be underappreciated or underfunded. Early-stage companies need capital and advisory services to reach their commercial
potential.
The healthcare industry is
primed for new technologies and business models due to the increasing cost of healthcare and due to the increasing pressure to add value
to the system. We believe that lower-value segments of healthcare will be burdened by the pressures of cost cutting, while companies or
segments that deliver superior products and services, with better clinical and non-clinical outcomes, will thrive. Successful companies
will be data driven, consumer focused, operationally efficient and transfer best-in-class standards globally. Our team takes a holistic
approach to investment opportunities and conduct stringent due diligence to screen such companies. We see opportunities for companies
that address global healthcare cost pressures by: succeeding in disruptive innovation, thus justifying monies spent by delivering cures
or other breakthrough outcomes; delivering cost savings to address global healthcare cost pressures; or providing access to medicines,
as the marginal benefits from healthcare spending are highest when providing goods and services to those who do not already receive them.
Investment Criteria
We are focused on companies
in disruptive and other value-added subsegments of healthcare that have the potential for significant gains in the next five years. Our
ideal company will be institutionally backed, with a high-quality management team and a demonstrated ability to raise money from the private
capital markets. The segments we will target include biotechnology, medical technology and digital health.
The focus of our management
team is to create stockholder value by leveraging its experience to efficiently guide an emerging healthcare company towards commercialization.
Consistent with our strategy, we have identified the following general criteria and guidelines that we believe are important in evaluating
prospective target businesses. While we intend to use these criteria and guidelines in evaluating prospective businesses, we may deviate
from these criteria and guidelines should we see fit to do so:
Healthcare
Company Poised for Rapid Growth
We intend to primarily seek
to acquire one or more growth businesses with a total equity value of greater than 5 to 10 times the amount of the proceeds of our IPO.
We believe that there are a substantial number of potential target businesses with appropriate valuations that can benefit from a public
listing and new capital for growth to support significant revenue and earnings growth or to advance clinical programs. We do not intend
to acquire a start-up company.
Niche Leader
and Specialized Business with High Growth Potential
We intend to seek
target companies that have significant and underexploited expansion opportunities in a niche sector. This can be accomplished
through a combination of accelerating organic growth and finding attractive add-on acquisition targets. Our management team has
significant experience in identifying such targets and in helping target management assess the strategic and financial fit.
Similarly, our management has the expertise to assess the likely synergies and a process to help a target integrate acquisitions.
Additionally, our management team has extensive experience assisting healthcare companies raise money as they navigate the
regulatory approval process.
Benefits from
Being a U.S. Public Company (Value Creation and Marketing Opportunities)
We intend to seek target
companies that should offer attractive risk-adjusted equity returns for our stockholders. We intend to seek to acquire a target on terms
and in a manner that leverage our experience. We expect to evaluate a company based on its potential to successfully achieve regulatory
approval and commercialize its product(s). We also expect to evaluate financial returns based on (i) risk-adjusted peak sales potential
(ii) the potential of pipeline products and the scientific platform (iii) the ability to achieve the system cost savings, (iv) the
ability to accelerate growth via other options, including through the opportunity for follow-on acquisitions, and (v) the prospects
for creating value through other value creation initiatives. Potential upside, for example, from the growth in the target business’
earnings or an improved capital structure, will be weighed against any identified downside risks.
Potential
Benefit from Globalization Trends and Possession of Competitive Advantages
Target companies exhibit
unrecognized value or other characteristics that we believe have been misevaluated by the marketplace based on our company-specific analyses
and due diligence. For a potential target company, this process will include, among other things, a review and analysis of the company’s
capital structure, quality of current or future earnings, preclinical or clinical data, potential for operational improvements, corporate
governance, customers, material contracts, and the industry and trends. We intend to leverage the operational experience and disciplined
investment approach of our team to identify opportunities to unlock value that our experience in complex situations allows us to pursue.
These criteria are not intended
to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant,
on these general guidelines as well as other considerations, factors and criteria that our management may deem relevant.
Competition
In identifying, evaluating
and selecting a target business for our initial business combination, we may encounter intense competition from other entities having
a business objective similar to ours, including other blank check companies, private equity groups and leveraged buyout funds, and operating
businesses seeking strategic acquisitions. Many of these entities are well established and have significant experience identifying and
effecting business combinations directly or through affiliates. Moreover, many of these competitors possess greater financial, technical,
human and other resources than us. Our ability to acquire larger target businesses will be limited by our available financial resources.
This inherent limitation gives others an advantage in pursuing the acquisition of a target business. Furthermore, the requirement that
we acquire a target business or businesses having a fair market value equal to at least 80% of the value of the trust account (excluding
any taxes payable) at the time of the agreement to enter into the business combination, our obligation to pay cash in connection with
our public stockholders who exercise their redemption rights may not be viewed favorably by certain target businesses. Any of these factors
may place us at a competitive disadvantage in successfully negotiating our initial business combination.
Employees
We currently have three executive officers. These
individuals are not obligated to devote any specific number of hours to our matters but they intend to devote as much of their time as
they deem necessary to our affairs until we have completed our initial business combination. The amount of time they will devote in any
time period will vary based on whether a target business has been selected for our initial business combination and the stage of the initial
business combination process we are in. We do not intend to have any full-time employees prior to the completion of our initial business
combination.
For additional discussion of the general development
of our business, see our Registration Statement on Form S-1, as amended, filed with the SEC on November, 18, 2020 and our Registration Statement on Form S-4, filed with the SEC on July 28, 2021.
As a smaller reporting company, we are not required
to make disclosures under this Item.
ITEM 1B.
|
UNRESOLVED STAFF COMMENTS
|
Not applicable.
Our
executive offices are located at 250 W 55th St #3401, New York, NY 10019, and our telephone number is (646) 889-1200. Our executive offices
are provided to us by an affiliate of our sponsor. Commencing on December 2021, we have paid an affiliate of our sponsor a total
of $10,000 per month for office space, utilities and secretarial support. We consider our current office space adequate for our current
operations.
ITEM 3.
|
LEGAL PROCEEDINGS
|
We may be subject to legal
proceedings, investigations and claims incidental to the conduct of our business from time to time. We are not currently a party to any
material litigation or other legal proceedings brought against us. We are also not aware of any legal proceeding, investigation or claim,
or other legal exposure that has a more than remote possibility of having a material adverse effect on our business, financial condition
or results of operations.
ITEM 4.
|
MINE SAFETY DISCLOSURES
|
Not Applicable.
part
II
ITEM 10.
|
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
|
The following table sets forth information about
our directors and executive officers.
Name
|
|
Age
|
|
Position
|
Andrew McDonald, Ph.D
|
|
47
|
|
Chairman, Chief Executive Officer and Board Member
|
Michael Rice
|
|
57
|
|
Chief Operating Officer and Board Member
|
David Dobkin
|
|
42
|
|
Chief Financial Officer and Board Member
|
Thomas Wynn
|
|
52
|
|
Board Member
|
Thomas Mathers
|
|
54
|
|
Board Member
|
Elizabeth Barrett
|
|
59
|
|
Board Member
|
Graham Walmsley
|
|
34
|
|
Board Member
|
Scott Janssen
|
|
52
|
|
Board Member
|
Andrew
McDonald, has been our Chief Executive Officer and Board member since December 2019, and is an experienced healthcare investment
professional with expertise in identifying transformative products and technologies in all stages of development. Andrew was the Chairman
and Chief Executive Officer of LifeSci Acquisition Corp., a special purpose acquisition company, from June 2019 until its merger with
Vincerx Pharma Inc. in December 2020. Andrew has served as the Chief Executive Officer of Attune Pharmaceuticals since March 2015 and
is a Founding Partner of LifeSci Advisors and LifeSci Capital. Prior to founding LifeSci, Andrew served as senior biotechnology analyst
at Great Point Partners, a dedicated life science hedge fund, from 2006 to 2008. From 2004 to 2006, Andrew was Head of Healthcare Research
and a Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew
was a medicinal chemist at Cytokinetics from 2001 to 2004, where he discovered and developed a promising anti-cancer agent now in clinical
trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer. Andrew received a Ph.D. in organic chemistry from UC
Irvine and completed his B.S. in chemistry at UC Berkeley. Andrew holds the Series 7, 24, 63, 79, 86, and 87 licenses.
Michael
Rice, has been our Chief Operating Officer and Board member since December 2019, and has experience in portfolio management,
corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the
co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was
a Managing Director at ThinkEquity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring
and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at
Banc of America, serving large hedge funds and private equity healthcare funds. Michael was the Chief Operating Officer and a director
of LifeSci Acquisition Corp., a special purpose acquisition company, from June 2019 until its merger with Vincerx Pharma Inc. in December
2020. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist.
David
Dobkin, has been our Chief Financial Officer and Board member since December 2019, and is an experienced healthcare capital
markets investment banker with a career focused on helping high-growth life science, medical device, and healthcare IT companies achieve
their financial and strategic goals. David was the Chief Financial Officer and a director of LifeSci Acquisition Corp., a special purpose
acquisition company, from June 2019 until its merger with Vincerx Pharma Inc. in December 2020. David has worked with companies developing
a wide range of technologies and brings extensive strategic advisory and execution capability to his clients. David has experience with
both traditional and non-traditional forms of equity and debt offerings in both the U.S. and abroad. He is a regular speaker on growth
capital formation at conferences across the United States and Canada. Prior to joining LifeSci Capital, David was a Managing Director
at Boustead Securities. Prior to that, in 2015, David founded Dobkin & Company, an investment bank tailored for entrepreneur-led companies
focused on seed and growth equity and capital. Previously, David worked in various capacities with the New Zealand Government facilitating
capital formation on behalf of regional companies and government agencies with a focus on securing strategic foreign direct investment.
David has tremendous experience conducting cross-border transactions. Prior to October 2010, David worked for Lazard Frères, one
of the world’s preeminent financial advisory and asset management firms, where he facilitated and advised on cross-border mergers
and acquisitions transactions in excess of $2.5 billion. Prior to joining for Lazard Frères, David began his career in the Healthcare
investment banking group for Wasserstein Perella based in New York. At Wasserstein Perella, David advised healthcare companies on capital
formation as well as strategic alternatives. David conducted graduate research in stem cell bioengineering and received a Master of Science,
Biomedical Engineering, from the University of Southern California. David also received a B.S. in Biomedical Engineering, from Columbia
University. David holds the Series 63, 79, and 82 licenses.
Thomas
Wynn, a Board member serving as chair of our Audit Committee and member of our Compensation Committee, has been a
portfolio manager at Monashee Investment Management since 2011. From 1995 to 2011, he co-founded and served as the Managing Director
of Leerink Swann LLC, a Boston based healthcare investment bank. From 1991 to 1995, he worked at Lehman Brothers. Thomas received
his B.A from Fairfield University and J.D. from Suffolk University. We believe Thomas is qualified to sit on our Board due to
long-running experience in healthcare investing and advisory services.
Thomas
Mathers, a Board member serving as chair of our Nominating Committee and member of our Audit Committee, founded and has been
the President and CEO at Allievex Corporation, a company neurodegenerative diseases, since April 2018. He has also been a General
Partner at Pappas Ventures V, a venture capital company, since February 2018. Prior to Pappas Capital and Allievex, from June 2010 to
March 2017, Tom was the President and CEO of CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD), a biotechnology company founded by Pappas Capital,
which focused on the development of lasmiditan for the acute treatment of migraine headaches. Eli Lilly & Company acquired CoLucid
in March 2017 in an all cash transaction for nearly $1 billion. Prior to CoLucid, he was President and CEO of Peptimmune, Inc.; President
and CEO of Cell Based Delivery, Inc; Vice President and General Manager of Cardion AG; and Vice President of Strategic Development at
Genzyme Corporation. Tom currently serves as a Trustee of Butler University and is co-founder and Chairman of Déclion Holdings,
a biopharmaceutical company focused on the discovery and development of innovative treatments for neurodegenerative diseases. He is also
a business advisor to the Progeria Research Foundation, and previously served on the board of directors for the Biotechnology Industry
Organization for nine years, where he was active in the policy areas of capital formation, bioethics, intellectual property, and regulatory
policy. From 1988 to 1991, Tom served as a captain in the United States Army and was awarded several medals for his services as an AH-64
Apache helicopter pilot in the Gulf War. We believe Thomas is qualified to sit on our Board due to his long-running experience in early
stage investing and experience on company boards.
Graham
Walmsley, a Board member and member of our Compensation Committee and Nominating Committee, has been the General Partner of
Logos Global Management, LP, a biotechnology-focused investment partnership based in San Francisco, since August 2019. He was a principal
at Versant Ventures, a leading healthcare investment firm, from July 2016 until August 2019. He was the head of Business Development at
Jecure Therapeutics, a developer of therapeutics targeting non-alcoholic steatohepatitis and liver fibrosis from June 2017 until March
2019. From April 2018 to December 2018, he was the Head of Business Development at Pipeline Therapeutics, a developer of neuro-regeneration
drugs. From July 2012 to June 2016, he was an Affiliated Trainee at Stanford Hospital & Clinics. He is currently a member of the board
of directors of ALX Oncology (Nasdaq: ALXO) and Akero Therapeutics (Nasdaq: AKRO). We believe Graham is qualified to sit on our board
due to his extensive experience in biotechnology investing and previous company board positions.
Elizabeth
Barrett, a Board member serving as chair of our Compensation Committee and member of our Audit Committee and Nominating Committee,
is a highly regarded industry leader with extensive experience leading business organizations and Fortune 500 pharmaceutical companies.
Since January 2019, Liz has served as President and CEO of UroGen Pharma. Prior to UroGen, from February 2018 to January 2019, Liz was
CEO of Novartis Oncology and a member of the Novartis Executive Committee. She previously was previously at Pfizer Inc. from March 2009
to January 2019, where she held numerous leadership positions, including Global President of Oncology, President of Global Innovative
Pharma for Europe, President of the Specialty Care Business Unit for North America, and President of United States Oncology. Prior to
Pfizer, Liz held positions at Cephalon Inc., where she was Vice President and General Manager of the Oncology Business Unit, and at Johnson
& Johnson. She started her career at Kraft Foods Group, Inc. Liz received a B.A. from the University of Louisiana and an M.B.A. from
Saint Joseph’s University. We believe Elizabeth is qualified to sit on our Board due to long-running leadership experience in healthcare
services and business management.
Scott
Janssen, a Board member, has served as Managing Director of LifeSci Associates since June 2020. Previously, he was the Chief
Accounting Officer at CMG Partners from August 2019 to April 2020. Scott has over 25 years of accounting, finance and operational experience
working within and consulting to public and private companies within the life science and technology space. Scott was a Managing Director
of the Connor Group from January 2014 to August 2019 to where he supported his clients by providing them accounting and operational consulting
services. Mr. Janssen spent six years of his career from January 1993 to November 1999 as an auditor with Ernst & Young and Grant
Thornton in the Bay Area and Los Angeles. He was a Managing Director at Connor Group, a consulting firm from January 2014 to August 2019.
Scott received a B.S. in Applied Mathematics from the University of California, Los Angeles. We believe Scott is qualified to sit on our
board due to his long-running experience in accounting and finance consulting roles.
Number and Terms of Office of Officers and Directors
Our
board of directors consists of eight directors and is divided into three classes with only one class of directors being elected in
each year and each class (except for those directors appointed prior to our first annual meeting of stockholders) serving a
three-year term. In accordance with Nasdaq corporate governance requirements, we are not required to hold an annual meeting
until one year after our first fiscal year end following our listing on Nasdaq. The term of office of the first class of directors,
consisting of Andrew McDonald, Michael Rice, David Dobkin and Scott Janssen will expire at our first annual meeting of stockholders.
The term of office of the second class of directors, consisting of Thomas Wynn, Thomas Mathers, Graham Walmsley and Elizabeth
Barrett, will expire at the second annual meeting.
Our officers are appointed by the board of directors
and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized
to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws provide that our directors may consist of
a chairman of the board, and that our officers may consist of chief executive officer, president, chief financial officer, executive vice
president(s), vice president(s), secretary, treasurer and such other officers as may be determined by the board of directors.
Director Independence
Nasdaq listing standards require that
within one year of the listing of our securities on the Nasdaq Capital Market we have at least three independent directors and that a
majority of our board of directors be independent. An “independent director” is defined generally as a person other than
an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company’s
board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of
a director. Our Board of Directors has determined that Thomas Wynn, Thomas Mathers, Graham Walmsley and Elizabeth Barrett are “independent
directors” as defined in the Nasdaq listing standards and applicable SEC rules. Our independent directors will have regularly scheduled
meetings at which only independent directors are present.
Committees of the Board of Directors
Our board of directors have three standing committees:
an audit committee, a compensation committee, and a Nominating Committee. Subject to phase-in rules and a limited exception, Nasdaq
rules and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised solely of independent
directors, and Nasdaq rules require that the compensation committee of a listed company be comprised solely of independent directors.
Audit Committee
Our Audit Committee has been
established in accordance with Section 3(a)(58)(A) of the Exchange Act and consists of Thomas Wynn, Thomas Mathers and Elizabeth
Barrett, each of whom are independent directors and are “financially literate” as defined under the Nasdaq listing
standards. Thomas Wynn serves as chairman of the Audit Committee. Our Board has determined that Thomas Wynn qualifies as an
“audit committee financial expert,” as defined under rules and regulations of the SEC.
The Audit Committee’s duties, which are specified
in our Audit Committee Charter, include, but are not limited to:
|
·
|
the appointment, compensation, retention, replacement, and oversight of
the work of the independent registered public accounting firm engaged by us;
|
|
·
|
pre-approving all audit and permitted non-audit services to be provided
by the independent registered public accounting firm engaged by us, and establishing pre-approval policies and procedures;
|
|
·
|
setting clear hiring policies for employees or former employees of the
independent registered public accounting firm, including but not limited to, as required by applicable laws and regulations;
|
|
·
|
setting clear policies for audit partner rotation in compliance with applicable laws and regulations;
|
|
·
|
obtaining and reviewing a report, at least annually, from the independent
registered public accounting firm describing (i) the independent registered public accounting firm’s internal quality-control procedures,
(ii) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry
or investigation by governmental or professional authorities within the preceding five years respecting one or more independent audits
carried out by the firm and any steps taken to deal with such issues and (iii) all relationships between the independent registered public
accounting firm and us to assess the independent registered public accounting firm’s independence;
|
|
·
|
reviewing and approving any related party transaction required to be disclosed
pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and
|
|
·
|
reviewing with management, the independent registered
public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence
with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our consolidated
financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial
Accounting Standards Board, the SEC or other regulatory authorities.
|
Compensation Committee
Our Compensation Committee consists of Elizabeth
Barrett, Thomas Wynn and Graham Walmsley, each of whom is an independent director. Elizabeth Barrett serves as chairman of the Compensation
Committee. Pursuant to our Compensation Committee charter, the functions of the Compensation Committee include, but not limited to:
|
•
|
reviewing and approving on an annual basis the corporate goals and objectives relevant to our President and Chief Executive Officer’s
compensation, evaluating our President and Chief Executive Officer’s performance in light of such goals and objectives and determining
and approving the remuneration (if any) of our President and Chief Executive Officer based on such evaluation;
|
|
•
|
reviewing and approving the compensation of all of our other executive officers;
|
|
•
|
reviewing our executive compensation policies and plans;
|
|
•
|
implementing and administering our incentive compensation equity-based remuneration plans;
|
|
•
|
assisting management in complying with our proxy statement and annual report disclosure requirements;
|
|
•
|
approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive
officers and employees;
|
|
•
|
producing a report on executive compensation to be included in our annual proxy statement; and
|
|
•
|
reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.
|
The charter provides that the compensation
committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and
will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before
engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee
will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.
Nominating Committee
Our Nominating Committee consists of Thomas Mathers,
Graham Walmsley and Elizabeth Barrett, each of whom is an independent director under Nasdaq’s listing standards. Thomas Mathers
is the chair of the nominating committee. The nominating committee is responsible for overseeing the selection of persons to be nominated
to serve on our board of directors. The nominating committee considers persons identified by its members, management, shareholders, investment
bankers and others.
The guidelines for selecting nominees, which are
specified in our Nominating Committee Charter, generally provide that persons to be nominated:
|
•
|
should have demonstrated notable or significant achievements in business, education or public service;
|
|
•
|
should possess the requisite intelligence, education and experience to make a significant contribution to the board of directors and
bring a range of skills, diverse perspectives and backgrounds to its deliberations; and
|
|
•
|
should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the
stockholders.
|
The nominating committee will consider a number
of qualifications relating to management and leadership experience, background and integrity and professionalism in evaluating a person’s
candidacy for membership on the board of directors. The nominating committee may require certain skills or attributes, such as financial
or accounting experience, to meet specific board needs that arise from time to time and will also consider the overall experience and
makeup of its members to obtain a broad and diverse mix of board members. The nominating committee does not distinguish among nominees
recommended by stockholders and other persons.
Code of Ethics
We
adopted a code of conduct and ethics applicable to our directors, officers and employees in accordance with applicable federal
securities laws. The code of ethics codifies the business and ethical principles that govern all aspects of our business. You will be
able to review our Code of Ethics by accessing our public filings at the SEC’s web site at www.sec.gov. In addition, a copy of our
Code of Ethics will be provided without charge upon request from us. We intend to disclose any amendments to or waivers of certain provisions
of our Code of Ethics in a Current Report on Form 8-K.
Section 16(a) Beneficial Ownership
Reporting Compliance
Section 16(a) of the Securities Exchange
Act of 1934, as amended, or the Exchange Act, requires our executive officers, directors and persons who beneficially own more than 10%
of a registered class of our equity securities to file with the Securities and Exchange Commission initial reports of ownership and reports
of changes in ownership of our shares of common stock and other equity securities. These executive officers, directors, and greater than
10% beneficial owners are required by SEC regulation to furnish us with copies of all Section 16(a) forms filed by such reporting
persons.
Based solely on our review of such forms furnished
to us and written representations from certain reporting persons, we believe that all filing requirements applicable to our executive
officers, directors and greater than 10% beneficial owners were filed in a timely manner.
ITEM 11.
|
EXECUTIVE COMPENSATION
|
Employment Agreements
We have not entered into any employment agreements
with our executive officers and have not made any agreements to provide benefits upon termination of employment.
Executive Officers and Director Compensation
No executive officer has received any cash compensation
for services rendered to us. No compensation of any kind, including finders, consulting or other similar fees, will be paid to any of
our existing stockholders, including our directors, or any of their respective affiliates, prior to, or for any services they render in
order to effectuate, the consummation of a business combination. However, such individuals will be reimbursed for any out-of-pocket expenses
incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable
business combinations. There is no limit on the amount of these out-of-pocket expenses and there will be no review of the reasonableness
of the expenses by anyone other than our board of directors and audit committee, which includes persons who may seek reimbursement, or
a court of competent jurisdiction if such reimbursement is challenged.
Compensation Committee Interlocks and Insider Participation
None of our officers currently serves, or in the
past year has served, as a member of the compensation committee of any entity that has one or more officers serving on our board of directors.
|
ITEM
12.
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS
|
The following table sets forth
as of June 30, 2021 the number of shares of common stock beneficially owned by (i) each person who is known by us to be the beneficial
owner of more than five percent of our issued and outstanding shares of common stock (ii) each of our officers and directors; and
(iii) all of our officers and directors as a group. As of June 30, 2021, we had 10,011,301 shares of common stock issued and outstanding.
Unless otherwise indicated,
we believe that all persons named in the table have sole voting and investment power with respect to all shares of common stock beneficially
owned by them. The following table does not reflect record of beneficial ownership of any shares of common stock issuable upon exercise
of the warrants, as the warrants are not exercisable within 60 days of June 30, 2021.
Name
and Address of Beneficial Owner(1)
|
|
Number of
Shares
Beneficially
Owned(2)
|
|
|
Percentage of
Outstanding
Shares
|
|
Andrew McDonald Ph.D.(1)
|
|
|
1,772,034
|
(2)
|
|
|
17.7
|
%
|
Michael Rice(1)
|
|
|
1,772,034
|
(2)
|
|
|
17.7
|
%
|
David Dobkin(1)
|
|
|
0
|
|
|
|
0
|
|
Thomas Wynn(1)
|
|
|
6,000
|
|
|
|
*
|
|
Thomas Mathers(1)
|
|
|
6,000
|
|
|
|
*
|
|
Graham Walmsley(1)
|
|
|
6,000
|
|
|
|
*
|
|
Elizabeth Barrett(1)
|
|
|
6,000
|
|
|
|
*
|
|
Scott Janssen(1)
|
|
|
6,000
|
|
|
|
*
|
|
All officers and directors as a group
|
|
|
1,802,034
|
|
|
|
18.0
|
%
|
(8
individuals)
|
|
|
|
|
|
|
|
|
RTW Investments, LP(3)
|
|
|
975,000
|
|
|
|
9.7
|
%
|
BlackRock, Inc.(4)
|
|
|
750,000
|
|
|
|
7.5
|
%
|
Cowen and Company, LLC(5)
|
|
|
682,776
|
|
|
|
6.8
|
%
|
Ikarian Capital, LLC(6)
|
|
|
512,450
|
|
|
|
5.1
|
%
|
Foresite Capital Management(7)
|
|
|
500,000
|
|
|
|
5.0
|
%
|
LifeSci Holdings LLC(1)(8)
|
|
|
1,772,034
|
|
|
|
17.7
|
%
|
* Less
than one percent.
(1)
|
The business address for these holders is c/o LifeSci Acquisition II Corp., 250 W. 55th St., #3401, New York, NY 10019
|
(2)
|
Consists of shares of common stock owned by LifeSci Holdings LLC, for which Michael Rice and Andrew McDonald are the managing members.
|
(3)
|
The registered holders of the referenced shares are funds and accounts under management by RTW Investments, LP. Roderick Wong, M.D.
is the Managing Partner of RTW Investments, LP, and has voting and investment power over the shares held by the funds and accounts, which
are the registered holders of the referenced shares. Mr. Wong disclaims beneficial ownership of the shares held by the funds, except to
the extent of his pecuniary interest therein. The address of such funds and accounts and such portfolio managers is 40 10th Avenue, Floor
7, New York, New York 10014.
|
(4)
|
The registered holders of the referenced shares are funds and accounts under management by BlackRock, Inc. The applicable portfolio
managers, as managing directors of such entity, have voting and investment power over the shares held by the funds and accounts, which
are the registered holders of the referenced shares. Such portfolio managers expressly disclaim beneficial ownership of all shares held
by such funds and accounts. The address of such funds and accounts and such portfolio managers is 55 East 52nd Street, New York, NY 10055.
|
(5)
|
The registered holders of the referenced shares are accounts under management by Cowen and Cowen Financial Products LLC (“CFP”).
Cowen has beneficial ownership of 7,776 shares and CFP has beneficial ownership of 675,000. Jeffrey Solomon, CEO of Cowen and CFP, has
voting and investment power with respect to the referenced shares. Accordingly, Mr. Solomon may be deemed to be the beneficial owner of
the foregoing shares of Common Stock. Mr. Solomon disclaims beneficial ownership of all shares held by such accounts. The address of such
accounts and portfolio manager is 599 Lexington Ave, New York, NY 10022.
|
(6)
|
The registered holders of the referenced shares are funds and accounts under management by Ikarian Capital, LLC. Ikarian Capital is
ultimately owned and controlled by Chart Westcott Living Trust, of which Chart Westcott serves as the sole trustee, and indirectly by
Neil Shahrestani. Messrs. Westcott and Shahrestani disclaim beneficial ownership of the shares held by the funds, except to the extent
of his pecuniary interest therein. The address of such funds and accounts and such portfolio managers is 100 Crescent Court, Suite 1620,
Dallas, Texas 75201.
|
(7)
|
The registered holders of the referenced shares are Foresite Capital Fund V, L.P. (“FCF V”) and Foresite Capital Opportunity
Fund V, L.P. (“FCF Opp V”). James Tananbaum is the managing member of each of Foresite Capital Management V, LLC (“FCM
V”), which is the general partner of FCF V, and Foresite Capital Opportunity Management V, LLC (“FCM Opp V”), which
is the general partner of FCF Opp V. Mr. Tananbaum may be deemed to have sole power to vote these shares. The address of Mr. Tananbaum,
FCF V and FCF Opp V is 600 Montgomery Street, Suite 4500, San Francisco, CA 94111.
|
(8)
|
Michael Rice and Andrew McDonald are the managing members of LifeSci Holdings LLC.
|
ITEM 13.
|
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
|
Founder Shares
On January 1, 2020, we issued
an aggregate of 2,156,250 founder shares to the Sponsor for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci Holdings
LLC transferred 215,625 founder shares to Chardan Healthcare Investments LLC, an investor in the Sponsor. The founder shares included
an aggregate of up to 153,990 shares of common stock that remained subject to forfeiture by the Sponsor, following the underwriters’
election to partially exercise their over-allotment option so that the number of founder shares would collectively represent 20% of our
issued and outstanding shares upon the completion of the IPO. On January 8, 2021, the underwriters’ election to exercise their remaining
over-allotment option expired unexercised, resulting in 615,959 shares no longer subject to forfeiture and the forfeiture of 153,990 shares.
Accordingly, as of January 8, 2021, there are 2,002,260 founder shares issued and outstanding.
The Sponsor and Chardan Healthcare
Investments LLC have agreed that, subject to certain limited exceptions, 50% of the founder shares will not be transferred, assigned,
sold or released from escrow until the earlier of (i) six months after the date of the consummation of a Business Combination or (ii)
the date on which the closing price of our shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock
dividends, reorganizations and recapitalizations) for any 20 trading days within any 30- trading day period commencing after a Business
Combination and the remaining 50% of the founder shares will not be transferred, assigned, sold or released from escrow until six months
after the date of the consummation of a Business Combination, or earlier, in either case, if, subsequent to a Business Combination, we
consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the stockholders having
the right to exchange their shares of common stock for cash, securities or other property.
PIPE Investment
In connection with the execution
of the Merger Agreement, we entered into the Subscription Agreements with the Subscribers pursuant to which the Subscribers have agreed
to purchase, and we agreed to sell to the Subscribers, an aggregate of 20,000,000 shares of LSAQ Common Stock, for a purchase price of
$10.00 per share and an aggregate purchase price of $200,000,000. The obligations to consummate the transactions contemplated by the Subscription
Agreements are conditioned upon, among other things, customary closing conditions and the consummation of the transactions contemplated
by the Merger Agreement.
The following table summarizes the participation
in the foregoing transaction by our directors, executive officers, and holders of more than 5% of any class of our capital stock as of
the date of such transaction:
Name
|
|
Purchase Price
|
|
RTW Investments, LP.(1)
|
|
$
|
30,000,000
|
|
BlackRock Health Sciences Trust II(2)
|
|
|
15,000,000
|
|
LifeSci Venture Partners II, LP(3)
|
|
|
1,000,000
|
|
|
(1)
|
The Subscribers of the shares are RTW Venture Fund Limited, RTW Master Fund, Ltd., and RTW Innovation Master Fund, Ltd., which are
affiliates of RTW Investments, LP.
|
|
(2)
|
BlackRock Health Sciences Trust II is a fund under management by a subsidiary of BlackRock, Inc.
|
|
(3)
|
LifeSci Venture Partners II, LP is an affiliate of the Sponsor. Andrew McDonald and Michael Rice are general partners and David Dobkin
is a limited partner of LifeSci Venture Partners II, LP.
|
Administrative Support Agreement
We entered into an agreement, commencing on November
20, 2020 through the earlier of the consummation of a Business Combination and our liquidation, to pay an affiliate of the Sponsor a total
of $10,000 per month for office space, utilities and secretarial support. Since December 2020, we incurred $10,000 in fees for these services
per month, of which such amount is included in accrued expenses in the accompanying unaudited condensed balance sheets.
Promissory Note — Related Party
On June 19, 2020, we issued an unsecured promissory
note to the Sponsor (the “Promissory Note”), pursuant to which we could borrow up to an aggregate principal amount of $175,000.
The Promissory Note was non-interest bearing and payable within 15 days of the Sponsor providing us with written notice of demand. The
outstanding balance under the Promissory Note of $175,000 was repaid at the closing of the IPO on November 24, 2020.
Related Party Loans
In order to finance transaction costs in connection
with a Business Combination, the Sponsor, an affiliate of the Sponsor, or our officers and directors may, but are not obligated to, loan
us funds from time to time or at any time, as may be required. Each working capital loan would be evidenced by a promissory note. The
working capital loans would be paid upon consummation of a Business Combination, without interest or, at the lender’s discretion,
up to $500,000 of such working capital loans may be converted into warrants of the post Business Combination entity at a price of $0.90
per warrant. In the event that a Business Combination does not close, we may use a portion of the proceeds held outside the Trust Account
to repay the working capital loans, but no proceeds held in the Trust Account would be used to repay the working capital loans. The warrants
would be identical to the Private Placement Warrants. As of June 30, 2021, we had no outstanding borrowings under the working capital
loans.
General
If any of our officers or directors becomes aware
of an initial business combination opportunity that falls within the line of business of any entity to which he or she has then-current
fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination
opportunity to such other entity. Our officers and directors currently have certain relevant fiduciary duties or contractual obligations
that may take priority over their duties to us.
Other than the foregoing, no compensation of any
kind, including any finder’s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid by us
to our sponsor, officers and directors, or any affiliate of our sponsor or officers, prior to, or in connection with any services rendered
in order to effectuate, the consummation of an initial business combination (regardless of the type of transaction that it is). However,
these individuals will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying
potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly
basis all payments that were made to our Sponsor, officers, directors or our or their affiliates and will determine which expenses and
the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of out-of-pocket expenses incurred by
such persons in connection with activities on our behalf.
We have entered into a registration rights agreement
with respect to founder shares and the Private Placement Warrants.
Pursuant to a registration rights agreement entered
into on November 20, 2020, the holders of the founder shares and the Private Placement Warrants are entitled to registration and stockholder
rights. In connection with the closing of the Merger, Science 37, we and certain stockholders of each of Science 37 and LSAQ who will
receive shares of common stock pursuant to the Merger Agreement, will enter into an amended and restated registration rights agreement,
which will become effective upon the consummation of the Business Combination.
Related Party Policy
Our Code of Ethics requires
us to avoid, wherever possible, all related party transactions that could result in actual or potential conflicts of interests, except
under guidelines approved by the board of directors (or the audit committee). Related-party transactions are defined as transactions in
which (1) the aggregate amount involved will or may be expected to exceed $120,000 in any calendar year, (2) we or any of our subsidiaries
is a participant, and (3) any (a) executive officer, director or nominee for election as a director, (b) greater than 5% beneficial owner
of our shares of common stock, or (c) immediate family member, of the persons referred to in clauses (a) and (b), has or will have a direct
or indirect material interest (other than solely as a result of being a director or a less than 10% beneficial owner of another entity).
A conflict of interest situation can arise when a person takes actions or has interests that may make it difficult to perform his or her
work objectively and effectively. Conflicts of interest may also arise if a person, or a member of his or her family, receives improper
personal benefits as a result of his or her position.
We also require each of our
directors and executive officers to annually complete a directors’ and officers’ questionnaire that elicits information about
related party transactions.
Our audit committee, pursuant
to its written charter, is responsible for reviewing and approving related- party transactions to the extent we enter into such transactions.
All ongoing and future transactions between us and any of our officers and directors or their respective affiliates will be on terms believed
by us to be no less favorable to us than are available from unaffiliated third parties. Such transactions will require prior approval
by our audit committee and a majority of our uninterested “independent” directors, or the members of our board who do not
have an interest in the transaction, in either case who had access, at our expense, to our attorneys or independent legal counsel. We
will not enter into any such transaction unless our audit committee and a majority of our disinterested “independent” directors
determine that the terms of such transaction are no less favorable to us than those that would be available to us with respect to such
a transaction from unaffiliated third parties. Additionally, we require each of our directors and executive officers to complete a directors’
and officers’ questionnaire that elicits information about related party transactions.
These procedures are intended
to determine whether any such related party transaction impairs the independence of a director or presents a conflict of interest on the
part of a director, employee or officer. To further minimize potential conflicts of interest, we have agreed not to consummate a business
combination with an entity which is affiliated with any of our initial stockholders unless we obtain an opinion from an independent investment
banking firm that the business combination is fair to our unaffiliated stockholders from a financial point of view.
Furthermore, in no event will
any of our existing officers, directors or initial stockholders, or any entity with which they are affiliated, be paid any finder’s
fee, consulting fee or other compensation prior to, or for any services they render in order to effectuate, the consummation of a business
combination.
Director Independence
Nasdaq listing standards require
that a majority of our board of directors be independent. For a description of the director independence, see “— Part III, Item
10 - Directors, Executive Officers and Corporate Governance”.
|
ITEM 14.
|
PRINCIPAL ACCOUNTANT FEES AND SERVICES.
|
The firm of WithumSmith+Brown, PC, or Withum,
acts as our independent registered public accounting firm. The following is a summary of fees paid to Withum for services rendered.
Audit Fees. For the year ended June 30, 2021
and for the period from December 18, 2019 (inception) through June 30, 2020, fees for our independent registered public accounting firm
were approximately $99,780 and $0, respectively, for the services Withum performed in connection with our Initial Public Offering and
the audit of our June 30, 2021 and 2020 financial statements included in this Annual Report on Form 10-K.
Audit-Related Fees. For the year ended June
30, 2021 and for the period from December 18, 2019 (inception) through June 30, 2020, our independent registered public accounting firm
did not render assurance and related services related to the performance of the audit or review of financial statements.
Tax Fees. For the year ended June 30, 2021 and for
the period from December 18, 2019 (inception) through June 30, 2020, fees for our independent registered public accounting firm were
approximately $3,605, for the services Withum performed in connection with tax compliance, tax advice and tax planning.
All Other Fees. For the year ended June 30,
2021 and for the period from December 18, 2019 (inception) through June 30, 2020, there were no fees billed for products and services
provided by our independent registered public accounting firm other than those set forth above.
Pre-Approval Policy
Our audit committee was formed upon the consummation
of our Initial Public Offering. As a result, the audit committee did not pre-approve all of the foregoing services, although any services
rendered prior to the formation of our audit committee were approved by our board of directors. Since the formation of our audit committee,
and on a going-forward basis, the audit committee has and will pre-approve all auditing services and permitted non-audit services to be
performed for us by our auditors, including the fees and terms thereof (subject to the de minimis exceptions for non-audit services described
in the Exchange Act which are approved by the audit committee prior to the completion of the audit).
part
IV
NOTES TO THE
CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2021
NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
LifeSci Acquisition II Corp.
(the “Company”) was incorporated in Delaware on December 18, 2019. The Company was formed for the purpose of entering into
a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business transaction with
one or more businesses or entities (a “Business Combination”).
Although the Company is not
limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to focus
on businesses operating in North America in the healthcare industry. The Company is an early stage and emerging growth company and, as
such, the Company is subject to all of the risks associated with early stage and emerging growth companies.
As of June 30, 2021, the
Company had not commenced any operations. All activity through June 30, 2021 relates to the Company’s formation and the initial
public offering (“Initial Public Offering”), which is described below, and identifying a target company for a Business Combination.
The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company
generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.
The registration statement
for the Company’s Initial Public Offering was declared effective on November 20, 2020. On November 24, 2020 the Company
consummated the Initial Public Offering of 8,009,041 shares of common stock (the “Public Shares”), which includes the partial
exercise by the underwriter of its over-allotment option in the amount of 509,041 Public Shares, at $10.00 per Public Share, generating
gross proceeds of $80,090,412 which is described in Note 3.
Simultaneously with the closing
of the Initial Public Offering, the Company consummated the sale of 3,146,454 warrants (the “Private Warrants”) at a price
of $0.90 per Private Warrant in a private placement to LifeSci Holdings, LLC (the “Sponsor”), an entity affiliated LifeSci
Capital LLC, generating gross proceeds of $2,831,809, which is described in Note 4.
Transaction costs amounted
to $1,858,498, consisting of $1,601,808 in cash underwriting fees and $256,690 of other offering costs.
Following the closing of
the Initial Public Offering on November 24, 2020, an amount of $80,090,412 ($10.00 per Public Share) from the net proceeds of the sale
of the Public Shares in the Initial Public Offering and the sale of the Private Warrants was placed in a trust account (the “Trust
Account”), and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company
Act of 1940, as amended, or the Investment Company Act, with a maturity of 183 days or less or in any open-ended investment company that
holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company,
until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account as described
below.
The Company’s management
has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private
Warrants, although substantially all of the net proceeds are intended to be applied toward consummating a Business Combination. The Company’s
initial Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of
the balance in the Trust Account (net of amounts previously released to the Company to pay its tax obligations and for working capital
purposes, subject to an annual limit of $250,000) at the time of the signing an agreement to enter into a Business Combination. The Company
will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting
securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as
an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business
Combination.
The Company will provide
its stockholders with the opportunity to redeem all or a portion of their Public Shares sold in the Initial Public Offering upon the completion
of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means
of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender
offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their Public Shares for a pro
rata portion of the amount then on deposit in the Trust Account (initially $10.00 per share, plus any pro rata interest earned on the
funds held in the Trust Account and not previously released to the Company to pay its tax obligations or for working capital purposes).
The Company will proceed
with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business
Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the
Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for
business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the
redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer
documents with the SEC prior to completing a Business Combination. If, however, a stockholder approval of the transaction is
required by law, or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer
to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If
the Company seeks stockholder approval in connection with a Business Combination, the Sponsor and other initial stockholders
(collectively, the “Initial Stockholders”) have agreed to (a) vote their Founder Shares (as defined in Note 5), and any
Public Shares held by them in favor of a Business Combination and (b) not to convert any shares (including Founder Shares) in
connection with a stockholder vote to approve a Business Combination or sell any such shares to the Company in a tender offer in
connection with a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective
of whether they vote for or against the proposed transaction.
LIFESCI ACQUISITION II CORP.
NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS
JUNE 30, 2021
Notwithstanding the foregoing,
if the Company seeks stockholder approval of a Business Combination and the Company does not conduct redemptions pursuant to the tender
offer rules, a stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in
concert or as a “group” (as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”)), will be restricted from redeeming their shares with respect to more than an aggregate of 20% of the Public Shares.
The Company will have until
November 24, 2022 to consummate a Business Combination (the “Combination Period”). If the Company is unable to complete a
Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii)
as promptly as reasonably possible but no more than five business days thereafter, redeem 100% of the outstanding Public Shares, at a
per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of
taxes payable), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’
rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii)
as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s
board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case
to its obligations to provide for claims of creditors and the requirements of applicable law. The proceeds deposited in the Trust Account
could, however, become subject to claims of creditors.
The Sponsor and Chardan Healthcare
Investments LLC have agreed to (i) waive their redemption rights with respect to Founder Shares and any Public Shares they may acquire
during or after the Initial Public Offering in connection with the consummation of a Business Combination, (ii) to waive their rights
to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company fails to consummate a Business
Combination within the Combination Period and (iii) not to propose an amendment to the Company’s Amended and Restated Certificate
of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the
Company does not complete a Business Combination, unless the Company provides the public stockholders an opportunity to redeem their Public
Shares in conjunction with any such amendment. However, the Sponsor will be entitled to liquidating distributions with respect to any
Public Shares acquired if the Company fails to consummate a Business Combination or liquidates within the Combination Period.
In order to protect the amounts
held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services
rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction
agreement, reduce the amount of funds in the Trust Account to below $10.00 per share, except as to any claims by a third party who executed
a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s
indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act
of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against
a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to
reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all
vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or
other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of
any kind in or to monies held in the Trust Account.
Liquidity and Capital Resources
As of June 30, 2021, the Company had cash of $416,111 not held in the
Trust Account and available for working capital purposes. The Company does not believe it will need to raise additional funds in order
to meet the expenditures required for operating our business. However, if the estimate of the costs of identifying a target business,
undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company
may have insufficient funds available to operate its business prior to our Business Combination. Moreover, the Company may need to obtain
additional financing or draw on the Working Capital Loans (as defined below) either to complete a Business Combination or because it becomes
obligated to redeem a significant number of the public shares upon consummation of our Business Combination, in which case the Company
may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities
laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is
unable to complete the Business Combination because it does not have sufficient funds available, the Company will be forced to cease operations
and liquidate the Trust Account. In addition, following the Business combination, if cash on hand is insufficient, the Company may need
to obtain additional financing in order to meet our obligations.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying
consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles
generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and
regulations of the Securities and Exchange Commission (the “SEC”).
Emerging Growth Company
The Company is an
“emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our
Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not
being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the
Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any
golden parachute payments not previously approved.
LIFESCI ACQUISITION II CORP.
NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS
JUNE 30, 2021
Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an
emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences
in accounting standards used.
Use of Estimates
The preparation of consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues
and expenses during the reporting periods.
Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the
date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term
due to one or more future events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all
short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have
any cash equivalents as of June 30, 2021 and 2020.
Common Stock Subject to Possible Redemption
The Company accounts for its common stock subject to possible redemption
in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from
Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally
redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject
to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity.
At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption
rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly,
at June 30, 2021, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity
section of the Company’s consolidated balance sheets.
Offering Costs
Offering costs consist of legal, accounting, underwriting
fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs
amounting to $1,858,498 were charged to stockholders’ equity upon the completion of the Initial Public Offering.
Income Taxes
The Company complies with the accounting and reporting requirements
of ASC Topic 740 “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for
income taxes. Deferred income tax assets and liabilities are computed for differences between the consolidated financial statement and
tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable
to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to
reduce deferred tax assets to the amount expected to be realized.
ASC 740 prescribes a recognition threshold and a measurement attribute
for the consolidated financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For
those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The
Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized
tax benefits and no amounts accrued for interest and penalties as of June 30, 2021 and 2020. The Company is currently not aware of any
issues under review that could result in significant payments, accruals or material deviation from its position.
LIFESCI ACQUISITION II CORP.
NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS
JUNE 30, 2021
The Company may be subject
to potential examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may
include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal,
state and city tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially
change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since inception.
Net Loss Per Common Share
Net loss per common
share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The Company has not
considered the effect of warrants sold in connection with the private placement to purchase 3,146,454 shares of common stock in the calculation
of diluted loss per common share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion
of such warrants would be anti-dilutive under the treasury stock method.
The Company’s consolidated statements of operations include a
presentation of loss per share for common shares subject to possible redemption in a manner similar to the two-class method of loss per
share. Net income per common share, basic and diluted, for redeemable common stock is calculated by dividing the interest income earned
on the Trust Account, less applicable franchise and income taxes, by the weighted average number of redeemable common stock outstanding
for the period. Net loss per common share, basic and diluted, for non-redeemable common stock is calculated by dividing the net loss,
less income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the
period. Weighted average shares were reduced for the effect of an aggregate of 281,250 shares of common stock that were subject to forfeiture
if the over-allotment option was not exercised by the underwriters. Non-redeemable common stock includes the Founder Shares as these shares
do not have any redemption features and do not participate in the income earned on the Trust Account.
The following table
reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts):
|
|
Year Ended
June 30,
|
|
|
For the Period from
December 18,
2019 (Inception) Through
June 30,
|
|
|
|
2021
|
|
|
2020
|
|
Redeemable Common Stock
|
|
|
|
|
|
|
|
|
Numerator: Earnings allocable to Redeemable Common Stock
|
|
|
|
|
|
|
|
|
Interest Income
|
|
$
|
30,397
|
|
|
$
|
—
|
|
Franchise Tax
|
|
|
(30,397
|
)
|
|
|
—
|
|
Net Earnings
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
Denominator: Weighted Average Redeemable Common Stock
|
|
|
|
|
|
|
|
|
Redeemable Common Stock, Basic and Diluted
|
|
|
8,009,041
|
|
|
|
—
|
|
Earnings/Basic and Diluted Redeemable Common Stock
|
|
$
|
0.00
|
|
|
$
|
0.00
|
|
|
|
|
|
|
|
|
|
|
Non-Redeemable Common Stock
|
|
|
|
|
|
|
|
|
Numerator: Net Loss minus Redeemable Net Earnings
|
|
|
|
|
|
|
|
|
Net Loss
|
|
$
|
(561,449
|
)
|
|
$
|
(1,000
|
)
|
Redeemable Net Earnings
|
|
|
—
|
|
|
|
—
|
|
Non-Redeemable Net Loss
|
|
$
|
(561,449
|
)
|
|
$
|
(1,000
|
)
|
|
|
|
|
|
|
|
|
|
Denominator: Weighted Average Non-Redeemable Common Stock
|
|
|
|
|
|
|
|
|
Non-Redeemable Common Stock, Basic and Diluted
|
|
|
1,951,216
|
|
|
|
1,875,000
|
|
Loss/Basic and Diluted Non-Redeemable Common Stock
|
|
$
|
(0.29
|
)
|
|
$
|
0.00
|
|
LIFESCI ACQUISITION II
CORP.
NOTES TO THE
CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2021
Note: As of June 30, 2021 and
2020, basic and diluted shares are the same as there are no non-redeemable securities that are dilutive to the Company’s stockholders.
Concentration of Credit Risk
Financial instruments that
potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times
may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management
believes the Company is not exposed to significant risks on such account.
Fair Value of Financial Instruments
The fair value of the Company’s assets and
liabilities which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximate the carrying
amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature.
Warrant Classification
The Company accounts for
the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815-40-15-7D under
which the warrants do meet the criteria for equity treatment and must be recorded as equity.
Recent Accounting Standards
In August 2020, the Financial Accounting Standards
Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other
Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”)
to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial
conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining
to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible
debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings
per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective
January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1,
2021. We are currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash
flows.
Management does not believe that any other recently issued, but not
yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.
NOTE 3. INITIAL PUBLIC OFFERING
Pursuant to the Initial Public
Offering, the Company sold 8,009,041 Public Shares, which includes the partial exercise by the underwriters of their over-allotment option
in the amount of 509,041 Public Shares, at a purchase price of $10.00 per Public Share.
NOTE 4. PRIVATE PLACEMENT
Simultaneously with the closing
of the Initial Public Offering, the Sponsor purchased an aggregate of 3,146,454 Private Warrants at a price of $0.90 per Private Warrant
for an aggregate purchase price of $2,831,809. Each Private Warrant is exercisable to purchase one share of common stock at an exercise
price of $11.50 per warrant. If the Company does not complete a Business Combination within the Combination Period, the proceeds from
the sale of the Private Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable
law). There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Warrants.
NOTE 5. RELATED PARTY TRANSACTIONS
Founder Shares
On January 1, 2020, the Company issued an aggregate of 2,156,250 shares
of common stock (the “Founder Shares”) to the Sponsor for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci
Holdings LLC transferred 215,625 Founder Shares to Chardan Healthcare Investments LLC, an investor in the Sponsor. The Founder Shares
included an aggregate of up to 153,990 shares of common stock that remained subject to forfeiture by the Sponsor, following the underwriters’
election to partially exercise their over-allotment option so that the number of Founder Shares would collectively represent 20% of the
Company’s issued and outstanding shares upon the completion of the Initial Public Offering. On January 8, 2021, the underwriters’
election to exercise their remaining over-allotment option expired unexercised, resulting in 127,260 shares no longer subject to forfeiture
and the forfeiture of 153,990 shares. Accordingly, as of January 8, 2021 and June 30, 2021, there were 2,002,260 Founder Shares issued
and outstanding.
LIFESCI ACQUISITION II
CORP.
NOTES TO THE
CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2021
The Sponsor and Chardan Healthcare
Investments LLC have agreed that, subject to certain limited exceptions, 50% of the Founder Shares will not be transferred, assigned,
sold or released from escrow until the earlier of (i) six months after the date of the consummation of a Business Combination or (ii)
the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for
stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing
after a Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow
until six months after the date of the consummation of a Business Combination, or earlier, in either case, if, subsequent to a Business
Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all
of the stockholders having the right to exchange their shares of common stock for cash, securities or other property.
Administrative Support Agreement
The Company entered into an agreement, commencing
on November 20, 2020 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay an
affiliate of the Sponsor a total of $10,000 per month for office space, utilities and secretarial support. For the year ended June 30,
2021, the Company incurred $70,000 in fees for these services, of which is included in accounts payable and accrued expenses in the accompanying
consolidated balance sheets. For the year ended June 30, 2020 the Company did not incur any fees for these services.
Promissory Note – Related Party
On June 19, 2020, the Company issued an unsecured promissory note to the Sponsor (the “Promissory
Note”), pursuant to which the Company could borrow up to an aggregate principal amount of $175,000. On July 9, 2020 the Company
borrowed $175,000 from the Sponsor. The Promissory Note was non-interest bearing and payable within 15 days of the Sponsor providing the
Company with written notice of demand. The outstanding balance under the Promissory Note of $175,000 was repaid at the closing of the
Initial Public Offering on November 24, 2020. No future borrowings are permitted under this note.
Related Party Loans
In order to finance transaction
costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors
may, but are not obligated to, loan the Company funds from time to time or at any time, as may be required (“Working Capital Loans”).
Each Working Capital Loan would be evidenced by a promissory note. The Working Capital Loans would be paid upon consummation of a Business
Combination, without interest or, at the lender’s discretion, up to $500,000 of such Working Capital Loans may be converted into
warrants of the post Business Combination entity at a price of $0.90 per warrant. In the event that a Business Combination does not close,
the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held
in the Trust Account would be used to repay the Working Capital Loans. The warrants would be identical to the Private Warrants. As of
June 30, 2021 and 2020, the Company had no outstanding borrowings under the Working Capital Loans.
NOTE 6. COMMITMENTS
Risks and Uncertainties
Management continues to evaluate the impact of the COVID-19 pandemic
and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position
and/or search for a target company, the specific impact is not readily determinable as of the date of the consolidated financial statements.
The consolidated financial statements does not include any adjustments that might result from the outcome of this uncertainty.
Registration and Stockholder Rights
Pursuant to a registration
rights agreement entered into on November 20, 2020, the holders of the Founder Shares and the Private Warrants and any shares that may
be issued upon conversion of Working Capital Loans (and all underlying securities) will be entitled to registration and stockholder rights.
The holders of a majority of these securities are entitled to make up to two demands that the Company register such securities. The holders
of the majority of the Founders Warrants can elect to exercise these registration rights at any time commencing three months prior to
the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Warrants can
elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders
have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation
of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
The Sponsor and its related persons may not, with respect to the Private Warrants purchased by it, (i) have more than one demand registration
right at the Company’s expense, (ii) exercise their demand registration rights more than five (5) years from the effective date
of the registration statement of the Initial Public Offering, and (iii) exercise their “piggy-back” registration rights more
than seven (7) years from the effective date of the Initial Public Offering, as long as the Sponsor or any of its related persons are
beneficial owners of Private Warrants.
LIFESCI ACQUISITION II
CORP.
NOTES TO THE
CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2021
Underwriting Agreement
The Company granted the underwriters
a 45-day option from the date of the Initial Public Offering to purchase up to 1,125,000 additional Public Shares to cover over-allotments,
if any, at the Initial Public Offering price less the underwriting discounts and commissions. As a result of the underwriter’s
election to partially exercise the over-allotment option to purchase an additional 509,041 Public Shares, a total of 615,959 Public Shares
remained available for purchase at a price of $10.00 per Public Share. On January 8, 2021, the underwriters’ election to exercise
their remaining over-allotment option expired unexercised.
The underwriters were paid
a cash underwriting discount of $0.20 per Public Share, or $1,601,808 in the aggregate.
Business Combination Marketing Agreement
The Company has engaged LifeSci
Capital LLC and Ladenburg Thalmann & Co. Inc. (“Ladenburg Thalmann “) as advisors in connection with a Business
Combination to assist the Company in holding meetings with its stockholders to discuss the potential Business Combination and the target
business’ attributes, introduce the Company to potential investors that are interested in purchasing the Company’s securities
in connection with a Business Combination, assist the Company in obtaining stockholder approval for the Business Combination and assist
the Company with its press releases and public filings in connection with the Business Combination. The Company will pay LifeSci Capital
LLC and Ladenburg Thalmann a cash fee for such services upon the consummation of a Business Combination in an amount equal to 3.5% of
the gross proceeds of the Initial Public Offering, or $2,803,164, (exclusive of any applicable finders’ fees which might become
payable) with 75% of such fee payable to LifeSci Capital LLC and 25% to Ladenburg Thalmann; provided that up to 33% of the fee may be
allocated in the Company’s sole discretion to other third parties who are investment banks or financial advisory firms not participating
in Initial Public Offering that assist the Company in identifying and consummating a Business Combination.
Business Combination Agreement
On May 6, 2021, the Company entered into an
Agreement and Plan of Merger (the “Merger Agreement”) with LifeSci Acquisition II Merger Sub, Inc. (“Merger Sub”),
and Science 37, Inc. (“Science 37”), pursuant to which the Merger Sub will merge with and into Science 37, with Science
37 surviving the merger as the Company’s wholly-owned subsidiary (the “Merger”). The Company’s board of directors
has unanimously (i) approved and declared advisable the Merger Agreement, the Merger and the other transactions contemplated thereby
and (ii) resolved to recommend approval of the Merger Agreement and related matters by our stockholders.
Immediately prior to the effective time of the
Merger (the “Effective Time”) and subject to the consent of the holders of a majority of the then outstanding shares of Science
37’s Series A, Series, B, Series C, Series D and Series D-1 preferred stock, par value $0.0001 per share (collectively,
the “Science 37 Preferred Stock”), voting together as a single class on an as-converted basis, each issued and outstanding
share of Science 37 Preferred Stock will be converted into shares of the common stock, par value $0.0001 per share, of Science 37 (the
“Science 37 Common Stock”) at the then-applicable conversion rates (the “Science 37 Preferred Stock Conversion”).
At the Effective Time, each outstanding and unexercised warrant to
purchase shares of Science 37 capital stock (“Science 37 Warrant”) that is outstanding and unexercised immediately prior to
the Effective Time will be converted into a warrant exercisable to receive the Company’s common stock, in accordance with its terms.
From and after the Effective Time: (i) each Science 37 Warrant assumed by the Company may be exercised solely for shares of the Company’s
common stock; (ii) the number of shares of the Company’s common stock subject to each Science 37 Warrant assumed by the Company
will be determined by multiplying (A) the number of shares of Science 37 Common Stock, or the number of shares of Science 37 Common
Stock issuable upon exercise of the Science 37 Warrant that were subject to such Science 37 Warrant immediately prior to the Effective
Time, by (B) the Exchange Ratio, and rounding the resulting number up to the nearest whole number of shares of the Company’s
common stock; (iii) the per share exercise price for the Company’s common stock issuable upon exercise of each Science 37 Warrant
assumed by the Company will be determined by dividing the per share exercise price of Science 37 Common Stock subject to the Science 37
Warrant, as in effect immediately prior to the Effective Time, by the Exchange Ratio and rounding the resulting exercise price up to the
nearest whole cent; and (iv) any restriction on any Science 37 Warrant assumed by the Company will continue in full force and effect
and the terms and other provisions of such Science 37 Warrant will otherwise remain unchanged. The Exchange Ratio is defined in the Merger
Agreement to be the quotient of (i) 100,000,000 divided by (ii) the number of shares of Science 37’s Fully Diluted Capital
Stock (as defined in the Merger Agreement).
LIFESCI ACQUISITION II
CORP.
NOTES TO THE
CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2021
At the Effective Time, following the Science 37
Preferred Stock Conversion, each share of Science 37 Common Stock (including shares of Science 37 Common Stock outstanding as a result
of the Science 37 Preferred Stock Conversion, but excluding shares the holders of which perfect rights of appraisal under Delaware law)
will be converted into the right to receive such number of shares of the Company’s common stock equal to the Exchange Ratio (subject
to rounding mechanisms as described in the Merger Agreement) and a number of Earn-Out Shares (as defined below).
At the Effective Time, each outstanding option
to purchase shares of Science 37 Common Stock, whether or not then vested and exercisable, will be converted automatically (and without
any required action on the part of such holder of outstanding option) into an option to purchase shares of the Company’s common
stock equal to the number of shares subject to such option prior to the Effective Time multiplied by the Exchange Ratio, with the per
share exercise price equal to the exercise price prior to the Effective Time divided by the Exchange Ratio.
Following the closing of the Merger, former holders of shares of Science
37 Common Stock (including shares received as a result of the Science 37 Preferred Stock Conversion) and former holders of Science 37
stock options will be entitled to receive their pro rata share of up to 12,500,000 additional shares of the Company’s common stock
(the “Earn-Out Shares”) if, within a three-year period following May 6, 2021, the signing date of the Merger Agreement,
the closing share price of the Company’s common stock equals or exceeds any of two thresholds over any 20 trading days within a
30-day trading period (each, a “Triggering Event”) and, in respect of a former holder of Science 37 stock options, the holder
continues to provide services to the Company or one of the subsidiaries at the time of such Triggering Event.
In
connection with the execution of the Merger Agreement, LSAQ entered into subscription agreements (collectively, the “Subscription
Agreements”) with certain parties subscribing for shares of LSAQ Common Stock (the “Subscribers”) pursuant to which
the Subscribers have agreed to purchase, and LSAQ has agreed to sell to the Subscribers, an aggregate of 20,000,000 shares of LSAQ Common
Stock, for a purchase price of $10.00 per share and an aggregate purchase price of $200,000,000. The obligations to consummate the transactions
contemplated by the Subscription Agreements are conditioned upon, among other things, customary closing conditions and the consummation
of the transactions contemplated by the Merger Agreement.
The Merger Agreement contains
customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain
conditions as further described in the Merger Agreement.
NOTE 7. STOCKHOLDERS' EQUITY
Preferred Stock —
The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designations,
voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. At June 30,
2021 and 2020, there were no shares of preferred stock issued or outstanding.
Common Stock —
The Company is authorized to issue 30,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the Company’s
common stock are entitled to one vote for each share. At June 30, 2021 and 2020, there were 2,458,674 and 2,156,250 shares of common
stock issued and outstanding, excluding 7,522,627 and no shares of common stock subject to possible redemption, respectively.
Warrants —
The Private Warrants will become exercisable at any time commencing on the later of (1) one year after the closing of the Initial Public
Offering or (2) the consummation of a Business Combination; provided that the Company has an effective and current registration statement
covering the shares of common stock issuable upon the exercise of the Public Warrants and a current prospectus relating to such shares
of common stock.
The Private Warrants purchased
by the Sponsor will be exercisable on a cashless basis and not be exercisable more than five years from the commencement of sales of
the Initial Public Offering, in accordance with FINRA Rule 5110(g)(8)(A), as long as the Sponsor or any of its related persons beneficially
own these Private Warrants.
LIFESCI ACQUISITION II
CORP.
NOTES TO THE
CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2021
NOTE 8. INCOME TAX
The Company did not have any
significant deferred tax assets or liabilities as of June 30, 2021 and 2020.
The Company’s net deferred
tax assets are as follows:
|
|
June 30,
|
|
|
|
2021
|
|
|
2020
|
|
Deferred tax asset
|
|
|
|
|
|
|
|
|
Net operating loss carryforward
|
|
$
|
6,802
|
|
|
$
|
210
|
|
Startup/Organization Expenses
|
|
|
111,312
|
|
|
|
—
|
|
Total deferred tax asset
|
|
|
118,114
|
|
|
|
210
|
|
Valuation allowance
|
|
|
(118,114
|
)
|
|
|
(210
|
)
|
Deferred tax asset, net of allowance
|
|
$
|
—
|
|
|
$
|
—
|
|
The income tax provision consists
of the following:
|
|
June 30,
|
|
|
|
2021
|
|
|
2020
|
|
Federal
|
|
|
|
|
|
|
|
|
Current
|
|
$
|
—
|
|
|
$
|
—
|
|
Deferred
|
|
|
(117,904
|
)
|
|
|
(210
|
)
|
|
|
|
|
|
|
|
|
|
State
|
|
|
|
|
|
|
|
|
Current
|
|
$
|
—
|
|
|
$
|
—
|
|
Deferred
|
|
|
—
|
|
|
|
—
|
|
Change in valuation allowance
|
|
|
117,904
|
|
|
|
210
|
|
Income tax provision
|
|
$
|
—
|
|
|
$
|
—
|
|
As of June 30, 2021 and 2020,
the Company had $31,391 and $1,000, respectively, of U.S. federal and state net operating loss carryovers available to offset future
taxable income.
In assessing the realization
of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets
will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during
the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled
reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration
of all of the information available, management believes that significant uncertainty exists with respect to future realization of the
deferred tax assets and has therefore established a full valuation allowance. For the year ended June 30, 2021 and for the period from
December 18, 2019 (inception) through June 30, 2020, the change in the valuation allowance was $117,904 and $210, respectively.
A reconciliation of the federal
income tax rate to the Company’s effective tax rate at June 30, 2021 and 2020 is as follows:
|
|
June 30,
|
|
|
|
2021
|
|
|
2020
|
|
Statutory federal income tax rate
|
|
|
21.0
|
%
|
|
|
21.0
|
%
|
State taxes, net of federal tax benefit
|
|
|
0.0
|
%
|
|
|
0.0
|
%
|
Change in valuation allowance
|
|
|
(21.0
|
)%
|
|
|
(21.0
|
)%
|
Income tax provision
|
|
|
0.0
|
%
|
|
|
0.0
|
%
|
The Company files income tax
returns in the U.S. federal jurisdiction in various state and local jurisdictions and is subject to examination by the various taxing
authorities.
LIFESCI ACQUISITION II
CORP.
NOTES TO THE
CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2021
NOTE 9. FAIR VALUE MEASUREMENTS
The fair value of the Company’s
financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with
the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants
at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the
use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions
about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and
liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
|
Level 1:
|
Quoted
prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions
for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
|
|
|
|
|
Level 2:
|
Observable
inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities
and quoted prices for identical assets or liabilities in markets that are not active.
|
|
|
|
|
Level 3:
|
Unobservable
inputs based on an assessment of the assumptions that market participants would use in pricing the asset or liability.
|
The Company classifies its U.S. Treasury and equivalent
securities as held-to-maturity in accordance with ASC Topic 320 “Investments - Debt and Equity Securities.” Held-to-maturity
securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities
are recorded at amortized cost on the accompanying consolidated balance sheets and adjusted for the amortization or accretion of premiums
or discounts.
The Company classifies its securities in the Trust
Account that are invested in funds, such as Mutual Funds or Money Market Funds, that primarily invest in U.S. Treasury and equivalent
securities as Trading Securities in accordance with ASC Topic 320 “Investments - Debt and Equity Securities. Trading Securities
are recorded at fair market value on the accompanying consolidated balance sheets.
At June 30, 2021, assets held in the Trust Account were comprised of
$0 in cash and $80,120,809 in a mutual fund that is invested primarily in U.S. Treasury Securities. Through June 30, 2021, the
Company has not withdrawn any of the interest earned on the Trust Account.
The following table presents information about the Company’s
assets that are measured at fair value on a recurring basis at June 30, 2021 and indicates the fair value hierarchy of the valuation inputs
the Company utilized to determine such fair value:
|
|
Trading Securities
|
|
Level
|
|
|
Fair Value
|
|
June 30, 2021
|
|
Mutual Fund
|
|
|
1
|
|
|
$
|
80,120,809
|
|
NOTE 10. SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions that occurred
after the balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, the Company
did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements.